Atopic dermatitis (AD), the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash. Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing, which can be debilitating. Until recently, there have been few options to treat more severe forms of AD, but with the approval of Dupixent (dupilumab), an IL-4 inhibitor, dermatologists have their first FDA approved biologic option to battle this disease. A host of other biologics and novel small molecules are in the pipeline and, as a result, the treatment paradigm for AD is expected to undergo a monumental shift over the next two to three years.
RealWorld Dynamix™: Moderate-to-Severe Atopic Dermatitis (US) is a large-scale patient audit of recently seen moderate-to-severe atopic dermatitis patients. To qualify, patients must be adults, seen within the past three months, currently pharmacologically treated (specifically for their AD), and classified as having moderate to severe disease.
Spherix will recruit 100 US dermatologists and 100 US allergists/immunologists to provide approximately 1,000 patient records which will include clinical and non-clinical demographics, robust patient histories, current and past treatment regimens, referral patterns, co-morbidities, quality of life metrics, office visits and touchpoints, candidacy for biologic therapy, physician feedback about therapy satisfaction (specifically if currently treated with Dupixent or Eucrisa), and candidacy for pipeline agents.
This is the first wave of this study.
Learn more about RealWorld Dynamix™ reports here.
- What is the patient profile of an AD patient currently treated with Dupixent and Eucrisa?
- How long will dermatologists wait to assess the efficacy of Dupixent and Eucrisa in their AD patients and what is the next step in their treatment plan if these agents are ultimately unsuccessful?
- If Dupixent and Eucrisa were unavailable, what treatments would patients be alternatively placed on?
- When in the course of an AD disease was the topic of biologic therapy initiated between the physician and patients and who initiated it?
- How many Dupixent patients were previously treated with an off-label biologic and what are the characteristics of these patients?
- What is the rate of off-label biologics use in AD and what do these patients look like?
- What is the patient profile of a moderate to severe AD patient considered a candidate for biologic/small molecule treatment but not currently treated with these agents?
- Why are moderate to severe patients who are considered biologic/small molecule candidates not currently prescribed Dupixent?
- What are the characteristics of moderate to severe AD patients who are not considered biologic/small molecule candidates?
- What is the likelihood of prescribing biologics/small molecules in development for moderate to severe AD patients ?
- What role are payers and patients playing in the use of biologics for the treatment of AD?
Pfizer (Eucrisa), Sanofi-Regeneron (Dupixent)
Classes: oral systemic immunomodulators, systemic corticosteroids (oral or injectable), topical corticosteroids, topical calcineurin inhibitors, off-label biologics and small molecules
AbbVie (upadacitinib), Amgen/Astra Zeneca(tezepelumab), AnaptysBIO (ANB020), Galderma (nemolizumab), Incyte (topical ruxolitinib), LEO Pharma (tralokinumab), and Vanda (tradipitant)